[go: up one dir, main page]

WO2015082376A3 - Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for the treatment of cancer - Google Patents

Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for the treatment of cancer Download PDF

Info

Publication number
WO2015082376A3
WO2015082376A3 PCT/EP2014/076051 EP2014076051W WO2015082376A3 WO 2015082376 A3 WO2015082376 A3 WO 2015082376A3 EP 2014076051 W EP2014076051 W EP 2014076051W WO 2015082376 A3 WO2015082376 A3 WO 2015082376A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
dihydroimidazo
quinazolines
cancer
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2014/076051
Other languages
French (fr)
Other versions
WO2015082376A2 (en
Inventor
Liu NINGSHU
Arne Scholz
Andrea HÄGEBARTH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of WO2015082376A2 publication Critical patent/WO2015082376A2/en
Publication of WO2015082376A3 publication Critical patent/WO2015082376A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to 2,3-dihydroimidazo(1,2-c)quinazoline derivatives as inhibitors of P13K kinase for the treatment or prophylaxis of a disease, particularly for the treatment of cancers and their metastases.
PCT/EP2014/076051 2013-12-03 2014-12-01 Use of pi3k-inhibitors Ceased WO2015082376A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13195567 2013-12-03
EP13195567.6 2013-12-03
EP14163752 2014-04-07
EP14163752.0 2014-04-07

Publications (2)

Publication Number Publication Date
WO2015082376A2 WO2015082376A2 (en) 2015-06-11
WO2015082376A3 true WO2015082376A3 (en) 2015-07-30

Family

ID=51999440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/076051 Ceased WO2015082376A2 (en) 2013-12-03 2014-12-01 Use of pi3k-inhibitors

Country Status (1)

Country Link
WO (1) WO2015082376A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108884159A (en) 2015-11-07 2018-11-23 茂体外尔公司 The composition use for cancer treatment blocked comprising tumor suppressor gene treatment and immunologic test point
EP3551226A1 (en) 2016-12-12 2019-10-16 MultiVir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
AU2018367909B2 (en) 2017-11-17 2022-03-10 Cellix Bio Private Limited Compositions and methods for the treatment of eye disorders
AU2019322487B2 (en) 2018-03-19 2024-04-18 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
WO2012062748A1 (en) * 2010-11-11 2012-05-18 Bayer Pharma Aktiengesellschaft Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2012062743A1 (en) * 2010-11-11 2012-05-18 Bayer Pharma Aktiengesellschaft Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
WO2012136549A1 (en) * 2011-04-05 2012-10-11 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
US20130184270A1 (en) * 2010-04-16 2013-07-18 Bayer Intellectual Property Gmbh Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
WO2014166820A1 (en) * 2013-04-08 2014-10-16 Bayer Pharma Aktiengesllschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
US20130184270A1 (en) * 2010-04-16 2013-07-18 Bayer Intellectual Property Gmbh Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
WO2012062748A1 (en) * 2010-11-11 2012-05-18 Bayer Pharma Aktiengesellschaft Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2012062743A1 (en) * 2010-11-11 2012-05-18 Bayer Pharma Aktiengesellschaft Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
WO2012136549A1 (en) * 2011-04-05 2012-10-11 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
WO2014166820A1 (en) * 2013-04-08 2014-10-16 Bayer Pharma Aktiengesllschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DIMITRIOS ZARDAVAS ET AL: "Emerging targeted agents in metastatic breast cancer", NATURE REVIEWS CLINICAL ONCOLOGY, NATURE, NY, US, vol. 10, 1 April 2013 (2013-04-01), pages 191 - 210, XP009174469, ISSN: 1759-4774 *
N. LIU ET AL: "BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110 and p110 Activities in Tumor Cell Lines and Xenograft Models", MOLECULAR CANCER THERAPEUTICS, vol. 12, no. 11, 29 October 2013 (2013-10-29), US, pages 2319 - 2330, XP055121310, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-12-0993-T *
SETH A. WANDER ET AL: "PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy", BREAST CANCER RESEARCH AND TREATMENT, vol. 138, no. 2, 21 February 2013 (2013-02-21), pages 369 - 381, XP055164167, ISSN: 0167-6806, DOI: 10.1007/s10549-012-2389-6 *
YAN XIE ET AL: "Identification of upregulated phosphoinositide 3-kinase [gamma] as a target to suppress breast cancer cell migration and invasion", BIOCHEMICAL PHARMACOLOGY, vol. 85, no. 10, 1 May 2013 (2013-05-01), pages 1454 - 1462, XP055164166, ISSN: 0006-2952, DOI: 10.1016/j.bcp.2013.03.001 *

Also Published As

Publication number Publication date
WO2015082376A2 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
IL291000A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
HRP20190152T1 (en) Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak)
EP3399968B8 (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
HUE061909T2 (en) Use of pyrazolo[1,5-a]pyrimidines as ATR kinase inhibitors for the treatment of cancer
NZ718190A (en) Substituted quinazolines for inhibiting kinase activity
EP3246328A4 (en) Quinazoline heterocyclic compound as egfr kinase inhibitor, and preparation and application thereof
MX2016002544A (en) Compounds useful as immunomodulators.
PH12016501232A1 (en) Pyrazolo[1,5-a]pyridine derivatives and methods of their use
MX367878B (en) Bicyclic heterocycles as fgfr inhibitors.
MX362215B (en) 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors.
JOP20140141B1 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
WO2015082376A3 (en) Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for the treatment of cancer
EP4169918B8 (en) Quinazoline derivatives as inhibitors of pi3k for the treatment of cancer
EP3071204A4 (en) Quinazoline derivatives as tam family kinase inhibitors
MX2012013527A (en) Fused quinazoline derivatives and uses thereof.
EP3089745A4 (en) Compounds, compositions, and methods for the treatment of cancers
WO2014160177A3 (en) Quinazoline inhibitors of pi3k
CR20150659A (en) DERIVATIVES OF PRODUCTION OF SUBSTITUTED TRIAZOLPIRIDINES
HK1220357A1 (en) Heteroaryl compounds and uses thereof
HK1248601A1 (en) Pyrimidine derivatives as kinase inhibitors and their therapeutical applications
CL2014001265A1 (en) Compounds derived from uracil, axl and c-met kinase inhibitors, useful in the treatment of cancer.
HK1233259A1 (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
AU2012901199A0 (en) Kinase inhibitors for the Treatment of Cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14805293

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14805293

Country of ref document: EP

Kind code of ref document: A2